Schaun Maximiliano I, Eibel Bruna, Kristocheck Melissa, Sausen Grasiele, Machado Luana, Koche Andreia, Markoski Melissa M
Laboratório de Cardiologia Molecular e Celular (LCMC), Instituto de Cardiologia/Fundação Universitária de Cardiologia, Porto Alegre, RS, Brazil.
Stem Cells Int. 2016;2016:2171035. doi: 10.1155/2016/2171035. Epub 2016 Jan 5.
The incidence of severe ischemic heart disease caused by coronary obstruction has progressively increased. Alternative forms of treatment have been studied in an attempt to regenerate myocardial tissue, induce angiogenesis, and improve clinical conditions. In this context, cell therapy has emerged as a promising alternative using cells with regenerative potential, focusing on the release of paracrine and autocrine factors that contribute to cell survival, angiogenesis, and tissue remodeling. Evidence of the safety, feasibility, and potential effectiveness of cell therapy has emerged from several clinical trials using different lineages of adult stem cells. The clinical benefit, however, is not yet well established. In this review, we discuss the therapeutic potential of cell therapy in terms of regenerative and angiogenic capacity after myocardial ischemia. In addition, we addressed nonpharmacological interventions that may influence this therapeutic practice, such as diet and physical training. This review brings together current data on pharmacological and nonpharmacological approaches to improve cell homing and cardiac repair.
由冠状动脉阻塞引起的严重缺血性心脏病的发病率已逐渐上升。人们已对其他治疗方式进行了研究，试图使心肌组织再生、诱导血管生成并改善临床状况。在此背景下，细胞疗法已成为一种有前景的替代方法，使用具有再生潜力的细胞，重点在于释放有助于细胞存活、血管生成和组织重塑的旁分泌和自分泌因子。使用不同谱系的成体干细胞进行的多项临床试验已证明了细胞疗法的安全性、可行性和潜在有效性。然而，其临床益处尚未得到充分证实。在本综述中，我们从心肌缺血后的再生和血管生成能力方面讨论了细胞疗法的治疗潜力。此外，我们探讨了可能影响这种治疗方法的非药物干预措施，如饮食和体育锻炼。本综述汇集了有关改善细胞归巢和心脏修复的药理学和非药理学方法的当前数据。
